186 results about "Chest pain" patented technology

A once-a-day oral milnacipran modified release formulation has been developed. The formulation comprises an extended release dosage unit (optionally containing the immediate release portion) coated with delayed release coating. The milnacipran composition, when administered orally, first passes through the stomach releasing from zero to less than 10% of the total milnacipran dose and then enters the intestines where drug is released slowly over an extended period of time. The release profile is characterized by a 0.05-4 hours lag time period during which less than 10% of the total milnacipran dose is released followed by a slow or extended release of the remaining drug over a defined period of time. The composition provides in vivo drug plasma levels characterized by Tmax at 4-10 hours and an approximately linear drop-off thereafter and Cmax below 3000 ng / ml, preferably below 2000 ng / ml, and most preferably below 1000 ng / ml. The composition allows milnacipran to be delivered over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.

The subject invention relates to the detection, diagnosis and risk stratification of clinical events such as acute coronary syndrome, in patients with signs and symptoms of suspected cardiac origin. In one embodiment, a clinical event in a patient is diagnosed by obtaining the patient's ECG, and at least one in vitro diagnostic assay, preferably an assay for a marker of ischemia, and optionally in vitro diagnostic assays for necrotic markers or other cardiac indicators, and combining the foregoing results in an algorithm to provide a diagnosis or a risk stratification of the clinical condition.

Methods and apparatus are provided for assessing the risk of an acute cardiovascular event that includes providing an endothelial or vascular function test to identify higher risk from lower risk individuals in a population of symptomatic individuals presenting with chest pain that have inconclusive results in ECG and cardiovascular marker tests, such as a tropinin test, and are administered for triage in hospital and additional tests such as ECG exercise and nuclear stress tests. The invention further provides methods and apparatus for assessing the vascular status and response of patients in clinical trials for cardiovascular therapies.

The present invention relates to a method for diagnosing myocardial infarction in a subject presenting with chest pain. The method is based on the determination of an amount of a cardiac troponin in a first sample from the subject obtained at presentation to a physician, and in a second sample obtained within one hour after the first sample. Moreover, the present invention envisages a method for ruling in myocardial infarction and a method for ruling out myocardial infarction. The said methods are also based on the determination of the amount of a cardiac troponin in a first sample from the subject obtained at presentation to a physician, and in a second sample obtained within one hour after the first sample.

The invention relates to a quality control method of Yixinshu traditional chinese medicine preparation for nourishing qi, restoring pulse, and activating blood circulation to dissipate blood stasis, belonging to medicine domain. The Yixinshu traditional chinese medicine preparation is composed of panax, astragalus root, radix salviae miltiorrhizae, lityturf root, chinese magnoliaving, chuanxiong rhizome and haw, with ability of nourishing qi, restoring pulse, activating blood circulation to dissipate blood stasis, nourishing yin and production of body fluid, applicable for the patients who suffer for deficiency of both vital energu and yin, heart-throb knotted pulse, chest oppression, chest pain, and angina pectoris of coronary heart disease. At present, on clinical usage, it is applied extensively in the treatment of angina pectoris, myocardial ischemia, various type of arrhythmias, atrial premature beat, chest pain, angina pectoris of coronary heart disease and so on. The said quality control method provides the criterion of detection, means of detection, technical method and so on for the associated production and detection mechanism, therefore the quality of Yixinshu traditional chinese medicine preparation can be better controlled to ensure the safety of the said preparation. The quality method can better guide the production to make the production process control more strict and reasonable, therefore the users could have an overall acquaintance with the product quality.

A once-a-day oral milnacipran pulsatile release composition has been developed that releases the drug in spaced apart “pulses”. The dosage forms are comprised of first, second and optional third dosage units, with each dosage unit having a different drug release profile. This dosage form provides in vivo drug plasma levels characterized by Cmax below 3000 ng / ml, preferably below 2000 ng / ml, and most preferably below 1000 ng / ml. The composition provides pulsatile release of milnacipran to produce a therapeutic effect over approximately 24 hours, when administered to a patient in need, resulting in diminished incidence or decreased intensity of common milnacipran side effects such as sleep disturbance, nausea, vomiting, headache, tremulousness, anxiety, panic attacks, palpitations, urinary retention, orthostatic hypotension, diaphoresis, chest pain, rash, weight gain, back pain, constipation, vertigo, increased sweating, agitation, hot flushes, tremors, fatigue, somnolence, dyspepsia, dysoria, nervousness, dry mouth, abdominal pain, irritability, and insomnia.

The invention discloses a medical combination for treating pulmonary heart disease and rheumatic heart disease and the preparation method thereof; the invention is prepared by peach kernel, safflower, angelica, charles abraham, Szechwan Lovage Rhizome, red peony root, achyranthes root, balloonflower root, bupleurum, citrus aurantium, and licorice. The medical combination of the invention has the efficacy of activating blood, promoting qi and ending pains, mainly for the treatment of pulmonary heart disease, rheumatic heart disease, the chest pain and headache caused by the clotted blood and the unsmooth blood flow in the chest, and also for coronary angina pectoris, chest contusion, rib chondritis chest pain, neurosis, deprementia of the concussion of brain sequela, dizziness headache, and other diseases. The invention has the advantages of simple formula, easy production, convenient taking by the patients, obvious efficacy, and wide application value.

A capsule or shell for oral administration at the onset of an acute adverse health event (e.g. chest pain). The shell has a plurality of impermeable enclosures in which dosage units are situated. The shell and impermeable enclosures, are made from materials which promptly disintegrate in the buccal, oral, lingual mucosa. The dosage unit may also be formulated for prompt disintegration when contacted by the mucosa.

The invention relates to a method for treatment of unstable coronary artery disease, which is characterised by an early revascularisation together with administration of a low molecular weight heparin. Preferably the low molecular weight heparin is administered up to revascularisation. The methods are also useful for treatment of unstable angina and not worsening chest pain and for treatment of non-Q-wave myocardial infarction (mild heart attack).

The invention discloses a new Chinese medicinal composition for treating lung carbunculosis and a preparation method thereof. The Chinese medicinal composition of the invention mainly comprises the following raw material medicaments: baical skullcap root, golden thread, snakegourd fruit, philippine violet herb, peach seed, honeysuckle, dahurian patrinia herb, dragon's blood, yanhusuo, incised notopterygium rhizome, divaricate saposhnikovia root, angelica dahurica, honey-fried pangolin scales, honey-fried tortoise plastron, honey-fried turtle shell and the like. The Chinese medicinal composition of the invention can be prepared into any common oral administration preparation according to the conventional method of Chinese medicinal preparations. The Chinese medicinal composition can improve symptoms such as fever and shaking with cold, cough, chest pain, dyspnea and even incapability of lying on the back due to cough and asthma, coughing of stench purulent phlegm or coughing of purulent blood and the like obviously, and has definite clinical effect, obvious curative effect and quick response. The Chinese medicinal composition of the invention is combined by adopting medicinal and edible medicaments formulated by National Formulary basically, and thus the Chinese medicinal composition has the advantages of low cost, no toxic or side effect and the like.

The invention discloses a novel traditional Chinese medicine combination for treating pulmonary atelectasis and a preparation method thereof. The traditional Chinese medicine combination mainly comprises the following bulk drugs: ephedra sinica stapf 2.ephedra equisetina bge., cinnamomum cassia presl, perilla, fineleaf schizonepeta herb, radix saposhnikoviae, root of lobed kudzuvine, chrysanthemum, mongolian snakegourd root, radix rehmanniae, baical skullcap root, lightyellow sophora root, tree peony bark, honeysuckle flower, mongolian dandelion herb, viola philipica cav., Indian buead, bristle inula, common coltsfoot flower, bitter apricot seed, stem of noble dendrobium, fragrant solomonseal rhizome, turtle shell, plastrum testudinis, chienshih, rosewood heart wood, storesin and the like. The traditional Chinese medicine combination can be prepared into any common oral preparations according to the conventional traditional Chinese preparation methods. The invention can notably improve short breath, dyspnea, cough, chest distress, chest pain, tachycardia, cyanosis, fever, pyohemoptysis and the like, and has definite and obvious clinical therapeutic effect and rapid treatment effect. As the traditional Chinese medicine combination basically adopts drugs of homology of medicine and food stipulated in national pharmacopoeia for combination, and the Chinese traditional medicine combination has the advantages of low cost, basically no side and toxic effects and the like.

The invention belongs to the technical field of medicines, and particularly relates to a medicine for treating pulmonary interstitial fibrosis, and a preparation method of the medicine. The medicine for treating pulmonary interstitial fibrosis comprises the following components: astragalus mongholicus, codonopsis pilosula, coastal glehnia root, salvia miltiorrhiza, angelica sinensis, ligusticum wallichii, honeysuckle, fructus forsythiae, scutellaria baicalensis, rhizoma pinelliae preparata, bulbus fritillariae cirrhosae and liquorice. According to the medicine, the astragalus mongholicus and codonopsis pilosula have the effects of tonifying Qi of lung and spleen; the coastal glehnia root has the effect of tonifying Yin of lung and spleen; the salvia miltiorrhiza, angelica sinensis, ligusticum wallichii, honeysuckle, fructus forsythiae, scutellaria baicalensis are used as the supplementary medicines and have the effects of clearing away stasis and resolving phlegm; the rhizoma pinelliae preparata and bulbus fritillariae cirrhosae are respective in moisture state and wet state and are assistant for resolving phlegm; and the liquorice is used for blending other medicines; and all the medicines are blended to realize the effects of supplementing Qi and nourishing Yin, and clearing away stasis and resolving phlegm, and as a result, the Qi can be recovered, the phlegm and stagnant heat can be cleared away, the Qi of the lung and spleen can be tonified by sweat evaporating and turbid descending, the fluid in human body can be smoothly balanced, and the functions can be recovered. The medicine has the functions of supplementing Qi and nourishing Yin, and clearing away stasis and resolving phlegm, and is mainly used for treating breathe hard symptom, weak symptom, dyspnea and tachypnea symptom, coughing symptom and chest pain symptom in clinic.

The invention provides a traditional Chinese medicine composition for curing tuberculous exadative pleurisy. The bulk drugs of the traditional Chinese medicine composition include flos farfarae, root bark of white mulberry, Chinese yam, euphorbia kansui, rhizoma panacis majoris, folium eriobotryae, radix stemonae, Chinese-date, inula flower, Chinese mahonia stems, rhizoma zingiberis, rhizoma sparganii, flowers carthami, folia perillae acutae, allium macrostemon, selaginella tamariscina, vine of multiflower knotweed, exocarpium, changium smyrnioides, poria cocos, semen coicis, turmeric, schisandra chinensis, semen lepidii, radix polygonati officinalis, rhizoma anemarrhenae, dayflower, polygonum cuspidatum, adenophora tetraphylla and kaladana. The traditional Chinese medicine composition reduces untoward effect of hydrothorax absorption, shortens course of disease, reduces pleural adhesions, pleural thickening and chest pain, enables hydrothorax absorption of patients to be quick, remarkably alleviates chest pain, and greatly reduces rate of pachynsis pleurae or pleural adhesion, thereby overcoming side effects caused by western drug therapy and having a certain curative effect on curing tuberculous exadative pleurisy.

The present invention discloses Lemaiwan pill and its preparation process, and relates to the improvement in preparation form of available granule. The present invention has the advantages of improved maintenance in active components, fast medicine releasing speed, high bioavailability, less irritation, accurate dosage, etc. The medicine has the functions of activating vital energy, promoting blood circulation and dispersing blood clots; is used for headache, dizziness, coronary heart disease, etc. and has obvious curative effect.

The invention provides a chest pain first-aid medical internet system and an application method thereof. A chest pain first-aid calling and dispatching command system, a chest pain first-aid flow risk control management system, a patient data real-time acquisition and remote transmission system, a chest pain first-aid electronic medical record system, an ambulance and salvage scene real-time video monitoring system, a remote first-aid and monitoring system, and a chest pain scoring system are integrated to form a chest pain first-aid management and quality control platform; and a hospital internal part and a hospital external part cooperate with each other, the treatment flow is optimized and normalized, the treatment time is shortened, the treatment efficiency is improved, and the casualty rate and medical disputes can be reduced.

The invention discloses an analgesic bone rheumatoid plaster. The analgesic bone rheumatoid plaster has the functions of relaxing tendons, activating blood circulation, removing blood stasis, dispelling pathogenic wind, dispelling cold, removing dampness, stimulating the menstrual flow, activating collaterals, invigorating bone, relieving pain, resolving hard mass, and the like. The indications comprise bumps, fall injuries, pain on wounds, intercostal neuralgia, lumbar sprain, chest pain, pain in neck, shoulder, waist and lower extremities, rheumatism, rheumatoid arthritis, bone hyperplasia, bone spur, gout, bone fractures, neuropathic pain, and the like, and the efficacy is remarkable. The analgesic bone rheumatoid plaster is characterized in that the plaster can be directly pasted without heating when in application, and the paste oil can not be flowed anywhere and only leave a light mark, thereby not affecting the sanitation and not generating a wound surface on the skin by long-term application.

The embodiment of the invention discloses a chest pain centre authentication data integration method and device, an apparatus and a memory medium. The method comprises the steps that a server receivesa data transmission request of a target apparatus or a target system; the target apparatus or the target system preestablishes network communication connection with the server, wherein the data transmission request comprises chest pain patient data information detected by the target apparatus or stored in the target system; if the server determines that the data transmission request passes security verification, the server carries out data check on the data information in the data transmission request; if the server determines that the data information is checked accurately, the server processes or stores the data information; and the server sends accurate response information matching the data transmission request to the target apparatus or the target system. Through application of the method, the chest pain centre data is automatically integrated, and the phenomenon that an error occurs in the chest pain centre authentication data, and various disputes about whether the data transmission is complete and accurate or not are avoided.

The invention relates to a Chinese herbal medicine composition which is used for treating lobar pneumonia. The Chinese herbal medicine composition comprises dayflower, baical skullcap, honeysuckle, peucedanum decursiva, herba patriniae, weeping forsythia, flatland wood, mulberry leaves, houttuyinie en Coeur, anemarrhena asphodeloides bunge, dandelion, lilyturf root, cidcada slough, giant knotweed, almond, plaster stone and / or carriers accepted by pharmacy. The invention also relates to a preparation method of the Chinese herbal medicine composition. The invention has the advantages of clearing away heat and toxic material, activating blood circulation to dissipate blood stasis and eliminating sputum and relieving coughs, applicable for curing the symptoms of chilling shiver, fever heat, chest pain and coughs caused by the lobar pneumonia.

The invention discloses a medicine composition for treating cardio-cerebral-vascular diseases and a preparation method and application thereof, belonging to the field of traditional Chinese medicines. The effective component of the medicine composition comprises total sapogenin and total alkaloid extracted from traditional Chinese herb trichosanthes kirilowii Maxim and allium macrostemon. The medicine composition which can be made into proper preparation forms has good treatment effects on coronary disease, angina, arteriosclerosis, chest pain, hyperlipoidemia and the like. The invention also discloses preparation methods of the total sapogenin and the total alkaloid.

The present invention relates to technology of medicinal preparation with component from plant in unknown structure, and is especially medicine comprising extract of 13 kinds of Chinese medicinal materials, including astragalus root, Dangshen, root of straight ladybell, ophiopogon root, arimonia herb. The medicine has reasonable recipe, modern preparation process, and the functions of benefiting vital energy, nourishing Yin, clearing away heat and toxic material, eliminating phlegm and relieving cough. It is suitable for the auxiliary treatment of vital energy and Yin deficiency and Yin deficiency internal heat type lung cancer in late stage, and has also high curative effect on shortness of breath, hypodynamia, cough, etc.

The invention relates to a traditional Chinese medicine for tonifying the kidneys, strengthening the heart, dissipating the blood stasis and activating the collaterals, which is a new high-efficiency, cheap, safe and convenient pure traditional Chinese medicine specifically used for treating coronary heart disease and stenocardia the symptoms of which comprise the failure and deficiency of the heart and the kidneys and the stasis of the blood vessels. The traditional Chinese medicine is prepared by comprising the components of epimedium, radix salviae miltiorrhizae, cassia twig, radix astragali, radix psuedostellariae, ophiopogon root, magnolia vine fruit, angelica, radix paeoniae rubra, hemlock parsley and safflower. Based on the heart-kidney correlation theory, the invention recognizes the coronary heart disease and the stenocardia with an angle that the failure and the deficiency of the heart and the kidneys are caused by the blood stasis of the vessels, and provides a theory that tonifying the kidneys, strengthening the heart, dissipating the blood stasis and activating the collaterals is a basic treating rule for preventing and treating the coronary heart disease and the stenocardia. The prescription uses the epimedium and the radix salviae miltiorrhizae as the monarch drug to tonify the kidneys and dissipating the blood stasis, uses the cassia twig, the astragali, the radix psuedostellariae, the angelica, the radix paeoniae rubra and the like as the minister drug to assist the monarch drug to supplement the qi, activate the yang, activate the blood circulation and dissipate the blood stasis, and uses the ophiopogon root and the magnolia vine fruit as the assistant and guide drug to nourish the yin and moisten the lung. When taking the medicine for a long term, patients suffering from the chest obstruction can improve the symptoms such as chest pain, chest distress, palpitation, limp and aching lumbus and knees and frequent urination at night and the like.

The invention discloses a medicament for treating primary bronchogenic carcinoma. Compound lung cancer capsule preparation consists of the following traditional Chinese medicines and packaging materials: ginseng, astragalus mongholicus, oldenlandia diffusa, ternate buttercup root, saffron crocus, pseudo-ginseng powder, musk, Chinese lobelia, curcuma zedoary, campsis grandiflora, rhizoma cyperi, peach kernel, akebia fruit, wall gecko, cordyceps sinensis and reishi shell-broken spore powder. The medicament disclosed by the invention fills up the blank in the subject filed for preventing and treating primary bronchogenic carcinoma-caused cough, hemoptysis, chest pain, phlegm and retained fluid, phlegm poison, lung poison, lung atelectasis, lung lump, lung accumulation and rushing respiration as well as pulmonary respiration-pulmonary atelectasis-caused deficiency of vital energy, imbalance of yin and yang, lung attacks due to deficiency of vital energy, qi depression of lung, disturbance of diffusion and downbearing, qi stagnation and blood stasis, phlegm cementation and lung cancers caused by lasting lung diseases. The medicament is innovative for the existing Chinese medicine treatment of the human in the world to lung cancer recovery clinical care culture.

The invention discloses a before-hospital first-aid method based on chest pain maps. The method can realize intelligent optimization of before-hospital first-aid and first-aid scheduling according tothe time space state map of a chest pain patient, wherein the chest pain maps mainly comprise four kinds of chest pain maps of body, knowledge, hospital and resource. The body chest pain map gathers information of body examination, medical record, daily chief complaint and the like of the patient. The information is transmitted to the knowledge chest pain map for per-determining a disease reason,risk reasoning and classification. A first-aid transportation target position of the high-risk chest pain patient is determined according to position information and clinic receiving capability presented in the hospital chest pain map. The resource chest pain map supplies position information of first-aid resources such as defibrillator, household doctor and first-aid medicaments in a field period, and supplies the position information of first-aid resources such as ambulance and hospital chest pain center in a transportation period. According to the before-hospital first-aid method, the fourkinds of chest pain maps of body, knowledge, hospital and resource are integrated for application, thereby facilitating guiding of optimized configuration of the first-aid resources, and supplying a scheduling plan with highest survival probability to the chest pain patient.

The invention belongs to a preparation, namely a blood conducting powder containing kudzuvine root and safflower, for treating hemiplegia. The preparation is prepared from the following traditional Chinese medicines in parts by weight: 6-80 parts of kudzuvine root, 5-50 parts of safflower, 10-120 parts of radix astragali, 10-50 parts of gastrodia elata, 10-50 parts of eucommia ulmoides, 10-30 parts of lumbricus, 10-30 parts of salviae miltiorrhiza, 10-30 parts of curcuma aromatica, 10-50 parts of acorus gramineus, 10-50 parts of dragon bone, 10-50 parts of panax notoginseng, 10-50 parts of ligusticum wallichii, 10-50 parts of radix paeoniae alba, 10-50 parts of Chinese angelica, 10-50 parts of cyathula officinalis and 10-50 parts of taxillus sutchuenensis. The blood conducting powder has the effects of tonifying qi, activating blood, dispersing blood stasis and dredging collaterals, and is used for apoplexy and apoplexy involving both collateral and meridian caused by qi deficiency, blood stasis and venation stasis as well as chest pain, chest distress, palpitation and shortness of breath caused by hemiplegia, numbness of limb, facial paralysis, stiff tongue and impeded speech and chest obstruction; cerebral infarction belongs to the syndromes, and the curative effect on the cerebral infarction is obvious. The blood conducting powder has the advantages of being noninvasive, painless, convenient to take, free of side effect and high in cure rate.

A traditional Chinese medicine detumescence patch adopts fifteen Chinese herbal medicines of resina draconis, safflower, peach kernel, prepared frankincense, prepared myrrh, woodlouse, and the like to prepare a patch for external use, and the patch is mainly used for treating traumatic injury, hemostasis swelling pains, back spraining and chest pains caused by mal-breathing, qi depression to blood stasis and fracture and other symptoms. The patch is prepared by the traditional process, the method is simple and the total effective rate of treatment can achieve 99%.

The invention discloses the new purpose of blood plasma miR-208a in an early marker for the diagnosis of acute myocardial infarction. The miRNA only has 18 to 25 nucleotide, and a mature body of the miRNA stably exists in cytoplasm, therefore, after the occurrence of the acute myocardial infarction, the miRNA is released into circulating blood earlier than structural protein substances (such as troponin), the raise of level can be detected at the early stage of myocardial infarction, and the blood plasma miR-208a can be used as the early marker for the diagnosis of acute myocardial infarction. With regard to the diagnoses to patients at the early stage of myocardial infarction (within three hours of stethalgia), good specific markers are currently unavailable, therefore, the blood plasma miR-208a has broad market prospect in finding out the marker applicable to the early diagnosis of acute myocardial infarction.

The invention provides a drug for treating arteriosclerosis, which is prepared by the following traditional Chinese medicines of: white peony, hawthorn, cherokee rose fruit, Codonopsis pilosula, lophatherum gracile, rhizoma atractylodis, silkworm larva, Polygonum cuspidatum, semen cassia, rhizoma alismatis, radix bupleuri, radix curcumae, fruit of Chinese wolfberry, Poria cocos, plantain seed, white atractylodes rhizome, Manis pentadactyla, gastrodia elata, Ligusticum wallichii, trigone, zedoary, leech, Polygonum multiflorum, frankincense, myrrh and oyster. The drug provided by the invention has better treatment effects on the common symptoms of the patients with arteriosclerosis, such as palpitation, flustering, chest pain, choking sensation in chest, headache, dizziness, cold and numb extremities, soreness and weakness of limbs, claudication, blurred vision, poor memory, insomnia and dreaminess, and also has better preventive effect on the city dwellers, the person who engages in intense brain works, the obese person, the heavy smoking person, the patient with hypertension, the patient with diabetes mellitus, the patient with hyperlipemia and the population susceptible to the arteriosclerosis; and the drug has the outstanding effects of no toxic or side effects, no untoward effect, and high cure rate.

The invention discloses a Chinese medicinal composition for treating damp-heat invasion blood stasis diabetic foot. Damp-heat invasion blood stasis diabetic foot comprises symptoms of red and swollen hot pain of limbs, purplish red and brightness of skin, dirty and odor fester of wounds, severe pain of lower limbs, anorexia, constipation, red tongue, yellowish and greasy coated tongue, chest pain, dark-red tongue and numb limbs. A medicine for oral administration comprises peach seed, red paeony root, Chinese angelica, gentian, root of red-rooted salvia, dahurian patrinia herb, largehead atractylodes rhizome, tuckahoe, bunge corydalis herb, zedoary, honeysuckle stem, safflower, szechuan lovage rhizome, common anemarrhena rhizome, suberect spatholobus stem, earthworm, rhubarb and astragalus; and externally applied medicament comprises dragon's blood, clematis root, honeysuckle flower, frankincense, myrrh, lightyellow sophora root, phellodendron, Sinkiang arnebia root, pubescent holly root, stir-fried garden burnet root, safflower, calcined gypsum, bletilla and plantain seed. The Chinese medicinal composition has the effects of invigorating qi and blood, promoting blood circulation to remove blood stasis, removing necrotic tissue and promoting tissue regeneration; the local micrangium barrier of the lower limbs is improved, blood circulation is promoted, and the necrotic tissue drops to fulfill the aim of tissue repair; the medicine for oral administration has the effects of controlling blood sugar effectively, regulating blood viscosity and reducing blood pressure; and the infection of feet is prevented, and the immunologic functions of human bodies are enhanced. The microcirculation of ulcer wounds can be improved effectively by the oral administration and external application of the Chinese medicines to fulfill the aim of healing the ulcer wounds.